Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPN | P05981 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2235621 | 0.78 | TRPA1 (0.50) | CYP1A2MAOAMAOBTRPA1TSHR | |
| SCHEMBL29421729 | 0.78 | GSK3A (0.46) | CYP1A2CYP2A6MAOAMAOBTRPA1 | |
| SCHEMBL232478 | 0.78 | CYP2A6 (0.48) | CYP1A2CYP2A6MAOAMAOBCES1 | |
| SCHEMBL461295 | 0.78 | GSK3A (0.46) | CYP1A2CYP2A6MAOAMAOBTRPA1 | |
| Hydrochloric Acid SCHEMBL8917627 | 0.76 | GSK3A (0.43) | CYP1A2CYP2A6MAOAMAOBTRPA1 | |
| SCHEMBL3106328 | 0.76 | GSK3A (0.43) | CYP1A2CYP2A6MAOAMAOBTRPA1 | |
| SCHEMBL3102143 | 0.76 | GSK3A (0.43) | CYP1A2CYP2A6MAOAMAOBTRPA1 | |
| SCHEMBL3107446 | 0.76 | GSK3A (0.43) | CYP1A2CYP2A6MAOAMAOBTRPA1 | |
| SCHEMBL30579936 | 0.76 | GSK3A (0.43) | CYP1A2CYP2A6MAOAMAOBTRPA1 | |
| SCHEMBL6517663 | 0.73 | GSK3A (0.40) | CYP1A2CYP2A6MAOAMAOBTRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234546-A | GPX4 inhibitors, pharmaceutical compositions thereof and their use in the treatment of GPX4 mediated diseases | 嘉兴优博生物技术有限公司 | 2023-06-06 | — | — | CN | claimed |
| WO-2021183702-A1 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-09-16 | — | — | WO | claimed |
| WO-2020207352-A1 | TRIAZINE BENZIMIDAZOLE COMPOUNDS AND MEDICAL USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2020-10-15 | — | — | WO | claimed |
| EP-4387613-A1 | CONJUGATES OF MONOCYCLIC BETA-LACTAMS AND SIDEROPHORE MIMETICS | University of Notre Dame du Lac (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240190817-A1 | METHODS OF TREATING CANCER | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4373832-A1 | PROCESSES OF MAKING ONAPRISTONE AND INTERMEDIATES THEREOF | Context Biopharma Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240165077-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISEASES | COGNITION THERAPEUTICS, INC. (US) | 2024-05-23 | — | — | US | disclosed |
| US-11981636-B2 | Compositions for treating neurodegenerative diseases | COGNITION THERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| US-20240150288-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20240139188-A1 | Arylamide Compounds For Treatment And Prevention Of Fungal Infections | INNOVATION PHARMACEUTICALS INC (US) | 2024-05-02 | — | — | US | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-RE37556-E1 | (ALKOXYPHENYL)THIAZOLE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-19 | — | — | US | disclosed |
| EP-1130017-A2 | Azole derivatives and their use as superoxide radical inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-05 | — | — | EP | disclosed |
| US-6080764-A | PROTECTING VARIOUS TISSUE CELLS FROM DISTURBANCES ASSOCIATED WITH ISCHEMIA AND BLOOD REPERFUSION IN HEART, BRAIN, KIDNEY, LUNG AND DIGESTIVE TRACT BY INHIBITING SUPEROXIDE-RELEASE BY NEUTROPHILIC LEUKOCYTES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-06-27 | — | — | US | disclosed |
| EP-0934937-A1 | Azole derivatives as superoxide radical inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
| US-5677319-A | THIAZOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| US-5643932-A | PREVENTS CELL DAMAGE AFTER ISCHEMIA AND RE-PERFUSION, SUBSTITUTED THIAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5262440-A | Treatment of neoplasms | ELI LILLY AND COMPANY (US) | 1993-11-16 | — | — | US | disclosed |
| US-5254582-A | Using n-((3,4-dichlorophenyl)amino)carbonyl)-2,3-dihydro-benzofuran-5-sulfonamide | ELI LILLY AND COMPANY (US) | 1993-10-19 | — | — | US | disclosed |
| EP-0513387-A1 | ACTIVE OXYGEN INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150288-A1 | ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, PSD | CYP1A2 3107/4885CYP2A6 4616/4885MAOA 2004/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | CYP1A2 1630/4885CYP2A6 1495/4885MAOA 177/4885 |
| US-20240190817-A1 | METHODS OF TREATING CANCER | MGMT, BRCA1, EP300 | CYP1A2 4479/4885CYP2A6 3311/4885MAOA 2362/4885 |
| US-11981636-B2 | Compositions for treating neurodegenerative diseases | HTT, RTN3, RB1 | CYP1A2 3551/4885CYP2A6 2386/4885MAOA 2129/4885 |
| US-20240139188-A1 | Arylamide Compounds For Treatment And Prevention Of Fungal Infections | NAT1, ERG28, AADAC | CYP1A2 191/4885CYP2A6 265/4885MAOA 302/4885 |
| US-20240165077-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGIC DISEASES | SNCA, ACHE, PARK7 | CYP1A2 3649/4885CYP2A6 3407/4885MAOA 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.